C. Guzmán

发表

In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.

J. Bueren, J. Jimeno, G. Faircloth, 2002, European journal of cancer.

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

M. Hidalgo, G. Weiss, H. Rosing, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

J. Schellens, H. Rosing, J. Beijnen, 2002, Anti-cancer drugs.

Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.

E. Raymond, J. Armand, S. Faivre, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

H. Rosing, E. Brain, J. Misset, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study.

A. Jimeno, F. Rivera, R. García-Carbonero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Value of Cytosolic p53 Protein in Breast Cancer

C. Ballestín, R. Colomer, H. Cortés-Funes, 2001, Tumor Biology.

Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens

I. Chirivella, A. Lluch, J. Pérez-Fidalgo, 2010, Breast Cancer Research and Treatment.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

J. Manola, G. Demetri, R. Maki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Angiogenin expression and prognosis in primary breast carcinoma.

R. Colomer, H. Cortés-Funes, C. Guzmán, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

J. Manola, G. Demetri, R. Maki, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.

A. Jimeno, R. Hitt, S. Gamarra, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pr e o p e r a t i ve CA 15.3 and prognosis in primary breast cancer

R. Colomer, H. Cortés-Funes, C. Guzmán, 2000 .

Long-term outcomes of patients following hospitalization for coronavirus disease 2019: a prospective observational study

J. Costa, M. Vaqué, J. Gali, 2021, Clinical Microbiology and Infection.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study 1

J. Schellens, H. Rosing, J. Beijnen, 2000 .

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

X. G. Del Muro, J. Pérez-Gracia, D. Castellano, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.